



10057532 10057532 MP, #7 #

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
**TRANSMITTAL FORM**

In re Application of Lyon et al. Attney Dkt: 003/240/SAP  
U.S. application serial no.: 10/057,532  
Filed: January 25, 2002  
Title: Recombinant *P. falciparum* Merozoite Protein-1<sub>42</sub> Vaccine

\*\*\*\*\*

25 June 2002

Honorable Commissioner of  
Patents and Trademarks  
Washington, D. C. 20231

Sir:

Transmitted for filing herewith are the following items:

- [x] Response to Notice to File Missing Parts of Application dated  
February 25, 2002  
[x] 4 sheets of Executed Declaration  
[14] Sheets of paper Sequence Listing  
[x] A diskette with computer readable form of Sequence Listing  
[x] Five sheets of Formal Drawings
- [x] Surcharge required [x] yes [ ] no \$130.00  
[x] Petition to extend the original due date of April 25, 2002  
to cover the date of this paper accompanied by the extension  
fee of: (Large/Small entity: [ ] 1 mo. \$110/\$55  
[x] 2 mos. \$400/\$200  
[ ] 3 mos. \$930/\$465  
[ ] 4 mos. \$1,470/735): \$ 400.00
- Fee required \$ 530.00

Please charge the above fee and any missing or inadequate fee re this paper to  
Deposit Account No. **21-0380** for which purpose a duplicate copy of this sheet is  
attached.

Respectfully submitted,

by Elizabeth Arwine Reg No 39,441  
for Elizabeth Arwine  
U.S. Agent No. 45,867

U.S. Army Medical and Materiel Command  
504 Scott Street  
Fort Detrick, Maryland 21702-5012  
ATTN: MCMR JA (Ms. Elizabeth Arwine- Patent Atty)

I hereby certify that this correspondence is being deposited with the United States  
Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Honorable Commissioner of Patents and Trademarks, Box Sequence, P.O.Box 2327  
Arlington, VA 22202, on the date of June 25, 2002.

07/03/2002 BABRAHA1 00000076 210380 10057532

01 FC:116 400.00 CH

Respectfully submitted,

by Sana A. Pratt  
Sana A. Pratt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Lyon et al. Attny Dkt: 003/240/SAP  
 U.S. application serial no.: 10/057,532  
 Filed: January 25, 2002  
 Title: Recombinant *P. falciparum* Merozoite Protein-1<sub>42</sub> Vaccine



25 June 2002

RESPONSE

Commissioner of Patents and Trademarks  
 Box Sequence Listing  
 Washington, D.C. 20231

Sir:

This is in response to the Notice to File Missing Parts of Application and the Notice to Comply with Sequence Listing Requirements dated February 25, 2002 in the subject application. Herewith submitted are the following:

- 1- Two Declaration forms executed by all inventors
- 2- Substitute paper and computer readable form (CRF) copy of the "Sequence Listing" in the subject application.
- 3- Substitute Formal Drawings

Kindly replace the originally filed sequence listing with the herein enclosed substitute sequence listing pages 1-14. I hereby state that the content of the substitute paper and computer readable copies are the same and do not include new matter.

Entry of the corrected Sequence Listing, Formal Drawings and executed Declaration is respectfully requested.


Respectfully submitted,

U.S. A. MRMCM  
 504 Scott Street  
 Fort Detrick, MD 21702-5012  
 ATTN: MCMR -JA (Elizabeth Arwine-Patent Atty)

By Elizabeth Arwine Reg. No. 39,441  
 U.S. Reg. No. 45,867

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box Sequence Listing, Box 2327, Arlington, VA 22202, on 25 June 2002.

By Sana A. Pratt  
 Sana A. Pratt  
 U.S. Reg. No. 39,441



In re Application of Lyon et al. Attny Dkt: 003/240/SAP  
U.S. application serial no.: 10/057,532  
Filed: January 25, 2002  
Title: Recombinant *P. falciparum* Merozoite Protein-1<sub>42</sub> Vaccine

\* \* \* \* \*

Honorable Commissioner of  
Patents and Trademarks  
Washington, D. C. 20231

Transmitted for filing herewith are the following items:

- Please charge the above fee and any missing or inadequate fee re this paper to Deposit Account No. **21-0380** for which purpose a duplicate copy of this sheet is attached.

by Elizabeth Arwine Key No. 39,441  
Elizabeth Arwine  
U.S. Agent No. 45,867

U.S. Army Medical and Materiel Command  
504 Scott Street  
Fort Detrick, Maryland 21702-5012  
ATTN: MCMR JA (Ms. Elizabeth Arwine- Patent Atty)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Honorable Commissioner of Patents and Trademarks, Box Sequence, P.O.Box 2327 Arlington, VA 22202, on the date of **June 25, 2002**.

by Sana A. Pratt  
Sana A. Pratt



#4

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/057,532	01/25/2002	Jeffrey A. Lyon	003/240/SAP

CONFIRMATION NO. 2344

## FORMALITIES LETTER



\*OC000000007529855\*

ATTN: MCMR-JA (Ms. Elizabeth Arwine-PATENT ATTY)  
U. S. Army Medical Research and Materiel Command  
504 Scott Street  
Fort Detrick, MD 21702-5012

Date Mailed 02/25/2002

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

07/03/2002 BABRAHA1 00000076 210380 10057532

FILED UNDER 37 CFR 1.53(b)

02 FC:105 130.00 CH

## Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter
- **The balance due by applicant is \$ 130.**

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment.

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
  - more than one figure is present and each figure is not labeled "Fig." with a consecutive Arabic numeral (1, 2, etc.) or an Arabic numeral and capital letter in the English alphabet (A, B, etc.)(see 37 CFR 1.84(u)(1));
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8,

2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice **MUST** be returned with the reply.*

*Y. G.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE